David Thomas Platt

US Patent:

6423314, Jul 23, 2002

Filed:

Dec 28, 2000

Appl. No.:

09/750726

Inventors:

David Platt - Cambridge MA 02139-9645

International Classification:

A61K 3900

US Classification:

4241841, 424 91, 424 934, 424 935, 424 9321, 424 9322, 4241851, 514 1, 514 2, 514 8, 514 12, 530350

Abstract:

The active, galactose binding site of proteins associated with metastatic tumor cells has been identified and sequenced. The polypeptide comprising the active site may be used as an immunotherapeutic agent. Identification of the site makes possible an in vivo diagnostic assay for metastatic cell as well as therapeutic methodologies and materials.

US Patent:

6500807, Dec 31, 2002

Filed:

Feb 1, 2000

Appl. No.:

09/495675

Inventors:

David Platt - Newton MA
Yan Chang - Chestnut Hill MA

Assignee:

Safescience, Inc. - Boston MA

International Classification:

A01N 4304

US Classification:

514 44, 514 54, 536 231

Abstract:

According to the present invention, there is provided a gene therapy material which includes a nucleic acid material and a carbohydrate wherein the carbohydrate preferably is a modified pectin. Also in accordance with the present invention, there is provided a gene therapy material including a nucleic acid material, a carbohydrate material associated with the nucleic acid material, and a protective coating disposed about the carbohydrate material.

US Patent:

6642205, Nov 4, 2003

Filed:

Sep 24, 2001

Appl. No.:

09/961681

Inventors:

Anatole Klyosov - Newton MA
David Platt - Newton MA

Assignee:

Pro-Pharmaceuticals, Inc. - Newton MA

International Classification:

A61K 9127

US Classification:

514 34, 514 42, 514432, 514 12, 514 8, 514 24, 5361231, 536 111

Abstract:

A pharmaceutical compound and a process for making the compound is provided where the compound includes a therapeutic agent, a spacer and a galactose, the spacer being covalently linked to the therapeutic agent at a first site on the spacer and covalently linked to the galactose by an ether bond at a second site on the spacer to form a conjugate. The conjugate may be used to treat a subject suffering from a medical condition, so as to reduce the side effects associated with the therapeutic agent by administering an effective dose of the conjugate to the subject so that the side effects in the subject are less then they would have been with the unconjugated therapeutic agent.

US Patent:

6645946, Nov 11, 2003

Filed:

Mar 27, 2001

Appl. No.:

09/818596

Inventors:

Anatole Klyosov - Newton MA
David Platt - Newton MA

Assignee:

Pro-Pharmaceuticals, Inc. - Newton MA

International Classification:

A01N 4304

US Classification:

514 54, 514 23, 514974, 514 34, 514256

Abstract:

Methods and compositions for reducing toxicity of a toxic agent are provided in which a polysaccharide, galactomannan is coadministered with a therapeutic agent in a liquid formulation to a subject to reduce toxicity of the agent for the subject.

US Patent:

6914055, Jul 5, 2005

Filed:

Aug 27, 2003

Appl. No.:

10/649130

Inventors:

Anatole Klyosov - Newton MA, US
David Platt - Newton MA, US

International Classification:

A01N043/04
A61K031/70
A61K031/715
A61K031/505

US Classification:

514 54, 514 23, 514 34, 514256, 514974

Abstract:

Methods and compositions for reducing toxicity of a toxic agent are provided in which a polysaccharide, galactomannan is coadministered with a therapeutic agent in a liquid formulation to a subject to reduce toxicity of the agent for the subject.

US Patent:

6982255, Jan 3, 2006

Filed:

Aug 27, 2003

Appl. No.:

10/649131

Inventors:

Anatole Klyosov - Newton MA, US
David Platt - Newton MA, US

International Classification:

A01N 43/04
A61K 31/715
A61K 31/70
A61K 31/505

US Classification:

514 54, 514 23, 514 34, 514256, 514974

Abstract:

Methods and compositions for reducing toxicity of a toxic agent are provided in which a polysaccharide, galactomannan is coadministered with a therapeutic agent in a liquid formulation to a subject to reduce toxicity of the agent for the subject.

US Patent:

7012068, Mar 14, 2006

Filed:

Mar 27, 2002

Appl. No.:

10/108237

Inventors:

Anatole Klyosov - Newton MA, US
David Platt - Newton MA, US

Assignee:

Pro-Pharmaceuticals, Inc. - Newton MA

International Classification:

A01N 43/04
A61K 31/715
A61K 31/70
A61K 31/505

US Classification:

514 54, 514 23, 514 34, 514256, 514974

Abstract:

Methods and compositions for treating cancer with a formulation are provided in which a polysaccharide, galactomannan, is co-administered with a therapeutic agent to a subject to reduce toxicity and/or enhance efficacy of the agent for the subject.

US Patent:

7491708, Feb 17, 2009

Filed:

Mar 1, 1993

Appl. No.:

08/024487

Inventors:

David Platt - Newton MA, US

International Classification:

A61K 31/715

US Classification:

514 54, 5361231, 536124, 536126, 536127, 435 32, 435101

Abstract:

A modified pectin consists essentially of neutral sugar sequences with a low degree of branching capable of preventing tumor cell migration and cell to cell and cell to substratum adhesion.